Characterization of early-onset and clinically-relevant novel phenotypes in the MPS IIIB mouse model will help to identify more sensitive markers to use in evaluation of potential therapies for Sanfilippo Syndrome B. Previous early markers include enhanced degradation of synaptophysin and priming of microglia by postnatal day 10 [51, 52], which require histopathological or biochemical analysis of collected tissue. Here, SYP is linked to mucopolysaccharidosis type 3B.